532 studies found for:    Open Studies | "Melanoma"
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Recruiting FDG-PET in Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Radiation: [18F]fluorodeoxyglucose;   Other: Molecular assays on biopsied tissue;   Device: positron emission tomography;   Device: computed tomography
2 Recruiting Combi-Neo Study for Stage IIIB-C and Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Malignant Melanoma Stage IV;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Procedure: Surgery
3 Unknown  Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
4 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
5 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
6 Recruiting RTA 408 Capsules in Patients With Melanoma - REVEAL
Conditions: Melanoma;   Unresectable (Stage III) Melanoma;   Metastatic (Stage IV) Melanoma
Interventions: Drug: Omaveloxolone Capsules (2.5 mg/capsule);   Drug: Ipilimumab (3 mg/kg);   Drug: Nivolumab (3 mg/kg)
7 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
8 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
9 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
10 Recruiting Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Conditions: Melanoma;   Uveal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
11 Not yet recruiting Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Conditions: Stages III Skin Melanoma;   Stages II Skin Melanoma;   Stage IB Skin Melanoma
Interventions: Drug: Propranolol hydrochloride;   Drug: Placebo pill
12 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
13 Not yet recruiting Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Oligometastatic Melanoma
Interventions: Drug: Nivolumab 1mg/kg;   Drug: Ipilimumab;   Drug: Nivolumab 3 mg/kg
14 Recruiting Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab;   Drug: Cobimetinib
15 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
16 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Melanoma;   Recurrent Uveal Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: IDO1 Inhibitor INCB024360;   Biological: MELITAC 12.1 Peptide Vaccine;   Other: Laboratory Biomarker Analysis
17 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
18 Recruiting Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Stage IIA Uveal Melanoma;   Stage IIB Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma
Interventions: Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
19 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
20 Recruiting Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Conditions: Unresectable Malignant Neoplasm;   Melanoma;   Metastatic Melanoma;   Stage IV Melanoma;   Stage III Melanoma
Intervention: Drug: Pembrolizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years